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The purinergic receptor subtype 7 (P2X7R) represents a novel molecular
target for imaging neuroinflammation via PET. GSK1482160, a potent
P2X7R antagonist, has high receptor affinity, high blood–brain bar-
rier penetration, and the ability to be radiolabeled with 11C. We re-
port the initial physical and biologic characterization of this novel
ligand. Methods: 11C-GSK1482160 was synthesized according to
published methods. Cell density studies were performed on human
embryonic kidney cell lines expressing human P2X7R (HEK293-
hP2X7R) and underwent Western blotting, an immunofluorescence
assay, and radioimmunohistochemistry analysis using P2X7R poly-
clonal antibodies. Receptor density and binding potential were
determined by saturation and association–disassociation kinetics,
respectively. Peak immune response to lipopolysaccharide treat-
ment in mice was determined in time course studies and analyzed
via Iba1 and P2X7R Western blotting and Iba1 immunohistochemis-
try. Whole-animal biodistribution studies were performed on saline- or
lipopolysaccharide-treated mice at 15, 30, and 60 min after radio-
tracer administration. Dynamic in vivo PET/CT was performed on
the mice at 72 h after administration of saline, lipopolysaccharide, or
lipopolysaccharide 1 blocking, and 2-compartment, 5-parameter
tracer kinetic modeling of brain regions was performed. Results:
P2X7R changed linearly with concentrations or cell numbers. For
high-specific-activity 11C-GSK1482160, receptor density and Kd
were 1.15 6 0.12 nM and 3.03 6 0.10 pmol/mg, respectively, in
HEK293-hP2X7R membranes. Association constant kon, dissocia-
tion constant koff, and binding potential (kon/koff) in HEK293-hP2X7R
cells were 0.2312 6 0.01542 min21nM21, 0.2547 6 0.0155 min21,
and 1.0277 6 0.207, respectively. Whole-brain Iba1 expression
in lipopolysaccharide-treated mice peaked by 72 h on immuno-
histochemistry, and Western blot analysis of P2X7R for saline- and
lipopolysaccharide-treated brain sections showed a respective
1.8- and 1.7-fold increase in signal enhancement at 72 h. Biodistri-
bution of 11C-GSK1482160 in saline- and lipopolysaccharide-treated
mice at 72 h was statistically significant across all tissues studied. In
vivo dynamic 11C-GSK1482160 PET/CT of mice at 72 h after admin-
istration of saline, lipopolysaccharide, or lipopolysaccharide 1 block-
ing showed a 3.2-fold increase and 97% blocking by 30 min. The total
distribution volumes for multiple cortical regions and the hippocam-
pus showed statistically significant increases and were blocked by an
excess of authentic standard GSK1482160. Conclusion: The current
study provides compelling data that support the suitability of 11C-
GSK1482160 as a radioligand targeting P2X7R, a biomarker of neuro-
inflammation.
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One essential step in the progression of brain diseases is
neuroinflammation (1), for which proinflammatory cytokines play
a central role (2). Recent work has shown that the pathogenesis of
neuroinflammation is mediated in part by the release of adenosine
or uridine derivatives from the damaged site, involving a family of
ionotropic purinergic receptors (P2XRs) with elevated expression
(3). Purinergic receptors are adenosine-triphosphate–gated nonse-
lective ion channels that are expressed on the cell surface mem-
branes of hematopoietic cells and include, but are not limited to,
macrophages, monocytes, and microglia (4,5). In particular, re-
ceptor subtype 7 (P2X7R) has been implicated in microglial pro-
liferation, phagocytosis of the injured site (6,7), and release of
proinflammatory cytokines (4,8–10). This mechanism is common
among a wide array of neurodegenerative inflammatory diseases,
which include Alzheimer disease, Parkinson disease, Huntington
disease, frontotemporal dementia, atrophic lateral sclerosis, mul-
tiple sclerosis, and traumatic brain injury (11–13).
P2X7R represents a novel molecular target for imaging neuro-
inflammation via PET. GSK1482160, a potent P2X7R antagonist,
has recently been labeled with 11C at our institution (14) as a poten-
tial biomarker of neuroinflammation. This article reports the initial




11C-GSK1482160 was synthesized according to methods described
by Gao et al. (14). The radiopharmaceutical was obtained with high
radiochemical purity (93% 6 3%), chemical purity (.95%), and spe-
cific activity (571.23 6 130.8 GBq/mmol), which are consistent with
prior reports from our institution (15) and others (16) where similar
synthetic N-11C methylation schemes of the amide precursors have
been used.
Cell Culture and Membrane Preparation
HEK293 cells expressing human recombinant P2X7 receptor
(hP2X7R) or human P2X4 receptor were obtained from B’SYS GmbH
and cultured according to the supplier’s procedure. Cells were grown
to 80% confluency and then rinsed with phosphate-buffered saline
(PBS), detached with trypsin, and harvested. Cell pellets were obtained
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by centrifugation at 200g for 5 min at 4C. Collected cell pellets were
frozen at 280C until membrane preparation. For the membrane prep-
aration, pellets from 10 T225 flasks were homogenized in 50 mM Tris-
HCl, 5 mM ethylenediaminetetraacetic acid, and 140 mM NaCl at
pH 7.4 and 4C. The homogenate was then centrifuged at 48,000g for
20 min at 4C, gently rinsed with deionized water, and then resuspended
in 50 mM Tris-HCl at pH 7.4 and 4C. This homogenate was then
centrifuged as before, with the resulting pellet being homogenized in
50 mM Tris-HCl at pH 7.4. Total protein concentration was determined
via the Bradford protein assay (Bio-Rad). Aliquots were stored in cryo-
vials at 280C until the day of assay.
Validation of Cell Line Receptor Expression
To validate the hP2X7R expression in HEK293 cells, low passage
(4–6) cells were plated, cultured, harvested, and pelleted as described
above. An aliquot of cells was counted via hemocytometer to obtain the
desired density. Cell pellets were resuspended in a cryomold with 1 mL
of Tissue-Tek optimal-cutting-temperature compound (Sakura Finetek),
serial-diluted with optimal-cutting-temperature compound to yield 500,
250, 125, and 62.5 million cells/mL, and frozen at 220C. Each mold
was cryosectioned at 20 mm, dry-mounted to gelatin-coated slides, and
fixed for 15 min in 4% paraformaldehyde in PBS. HEK293-hP2X7R
cells were also used for confirmatory assays, including immunofluores-
cence (n 5 3) and radioimmunohistochemistry (n 5 3). Blocking was
performed for 45 min in PBS with 5% bovine serum albumen
and 0.1% Triton-X100 (The Dow Chemical Company), followed by
incubation overnight at 4C in P2X7R primary antibody (APR-008;
Alomone) in PBS with 1% bovine serum albumen and 0.1% Triton-
X100 at a 1:200 dilution. There were three 5-min washes in PBS with
0.5% Triton-X100. Secondary antibodies were 1:800 IRDye 680LT goat
antirabbit IgG (H 1 L) for the immunofluorescence assay, and 1:1,000
125I-protein A (NEX146025UC; PerkinElmer) for the radioimmunohis-
tochemistry, both incubated 1 h at room temperature and washed as
described above. For detection, immunofluorescence assay slides were
imaged on an Odyssey near-infrared imager (LiCor) at 680 nm, whereas
radioimmunohistochemistry slides were exposed to a TR2025 phosphor
screen (GE Healthcare) overnight and read on a Typhoon FLA-7000IP
(GE Healthcare). To determine the protein level expression of hP2X7R
via Western blotting, a separate aliquot of cells was further serial-
diluted, yielding 12,500, 6,250, 3,125, 1,562, and 781 cells per sample.
HEK293-hP2X7R cells were digested in radioimmunoprecipitation as-
say buffer and run on Novex 10% tris-glycine gels (Invitrogen). The
resulting transfer on nitrocellulose was probed via Western blotting
techniques using the Millipore SNAP i.d. protein detection system with
Tris-buffered saline blocking buffer (LiCor). Primary antibody against
P2X7R (APR-008; Alomone) was used at 1:150 followed by IRDye
680LT goat antirabbit IgG (H1 L) secondary antibody at 1:6,000 (926-
68021; LiCor). Western blots (n 5 2) were imaged on an Odyssey
imager at 680 nm. In all cases, band intensities were quantified with
Image Studio Lite (version 5.2.5; LiCor).
11C-Standards
For each experiment, the highest concentration of radioactivity used
was diluted twice in assay buffer, followed by eleven 2-fold dilutions.
Twenty microliters of each dilution were then spotted onto a GF/B
UniFilter-96 plate (Perkin-Elmer) and allowed to air-dry until the end
of the experiment. An additional 20 mL of each dilution were added to
a scintillation vial containing 7 mL of Optiphase Hisafe 3 (Perkin-
Elmer) and counted on an LS6000 scintillation counter (Beckman).
Aliquots of the working concentrations of radioactivity used on each
day were counted in the same manner.
Radioligand Depletion Experiments
Ligand depletion experiments were performed to measure the
bound ligand concentration (n 5 3; 4 technical replicates per dose
level). Four replicates of membrane preparation (0.004–4.5 mg of
protein/mL of assay medium) were incubated with 0.3 nM and
5 nM 11C-GSK1482160 in a final volume of 0.2 mL in assay buffer
(50 mM Tris-HCl, pH 7.4, 0.1% bovine serum albumen) for 30 min
at 22C. To measure the total radioactivity added to the experiment,
20 mL of stock ligand (amount added to each experimental well) were
spotted onto a GF/B UniFilter plate and then allowed to air-dry. For
termination of the binding reaction, the samples were filtered onto GF/B
UniFilter plates that had been presoaked in 0.5% polyethyleneimine for
30 min using a UniFilter-96 cell harvester. The plates were washed
5 times with ice-cold saline, dried under a vacuum, and exposed to a
TR2025 phosphor screen for 20–60 min. Phosphor screens were then
read on a Typhoon FLA-7000IP along with 11C-calibration standards.
Radioligand Association and Dissociation Experiments
For the association study, membrane protein (0.054 mg of protein/mL
of assay medium) was incubated with 3 nM 11C-GSK1482160 at 22C.
The binding was started at different time points in reverse order and
terminated simultaneously in all samples at time zero by filtration as
described above. For the dissociation study, incubation of samples was
terminated after 30 min of association by adding 10 mM authentic
standard GSK1482160 solution in dimethyl sulfoxide and saline (14).
The competition reaction was assessed at different time points by rapid
filtration and exposed to a phosphor screen as described in “Radioligand
Depletion Experiments” (n 5 3; 8 technical replicates).
Radioligand Saturation Experiments
Membrane protein (0.054 mg of protein/mL of assay medium) was
incubated with increasing concentrations of 11C-GSK1482160 (0.15–
15,000 pM) at 22C for 20 min. Nonspecific binding was obtained
by incubation of adjacent samples with 10 mM authentic standard
GSK1482160. The assay was terminated by rapid filtration and expo-
sure to a phosphor screen as described in “Radioligand Depletion
Experiments” (n 5 3; 4 technical replicates per treatment).
Lipopolysaccharide Time Course
To demonstrate microglial activation and determine the peak of
the immune response, a lipopolysaccharide time course study was
conducted in which C57BL6 mice (n 5 4/treatment/time) were in-
jected intraperitoneally with saline or a 5 mg/kg dose of lipopolysac-
charide (O111:B4; Sigma-Aldrich) dissolved in PBS and returned to
their home cages for 24, 48, 72, and 96 h (saline and lipopolysaccha-
ride). At the time of harvesting, groups of mice were deeply anesthe-
tized using isoflurane and sacrificed via rapid decapitation. The brains
were rapidly removed and rinsed in chilled PBS, and the frontal cortex
was dissected, frozen on dry ice, and stored at 280C until use. For
Western blotting, protein was extracted from approximately 100 mg of
tissue that was weighed out and placed in a microcentrifuge tube with
100 mL of N-PER neuronal protein extraction reagent (Pierce Bio-
technology) on ice. The tissue was homogenized on ice for approxi-
mately 20 strokes with a pellet pestle, incubated for 10 min on ice, and
centrifuged at 10,000g for 10 min at 4C. The supernatant was col-
lected into fresh microcentrifuge tubes, protein content was deter-
mined via the Bradford assay, and aliquots were stored at 280C until
analysis. For Western blotting, tissue lysates were run on Novex gels
(Invitrogen) at 5 mg/lane. For Iba1, 10%–20% Tris-glycine gels were
used, with subsequent blotting performed on a SNAP i.d. system, accord-
ing to the manufacturer’s protocol, at a 1:1,000 dilution in Anti-Iba1
(EPR16588) primary antibody (ab178846; Abcam). For P2X7R, 10%
tris-glycine gels and Alomone antibody were used as described in “Cell
Line Receptor Expression Validation.” Both blots were probed second-
arily with IRDye 680LT goat antirabbit IgG (H1 L) secondary antibody
at a 1:6,000 dilution (926-68021) before imaging on an Odyssey imager
at 680 nm. The blots were stripped and reprobed for b-actin (ab8226;
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Abcam) at a 1:1,000 dilution in Tris-buffered saline buffer with
1:6,000 IRDye 800CW goat antimouse IgG (H 1 L) secondary anti-
body (926-32210l LiCor) before imaging on an Odyssey imager at
800 nm. In all cases, band intensities were quantified with Image Studio
Lite. On the basis of the results of the time course, a subset of brains
was postfixed overnight in 4% paraformaldehyde and then dehydrated
in gradient sucrose solution (20%–30%) at 4C. At completion, the
brains were rinsed in PBS, blotted dry, mounted into cryomolds with
Tissue-Tek optimal-cutting-temperature compound, frozen, and stored
at 280C until cryotomy. For immunohistochemistry analysis, the
brains from mice treated with saline or 72 h after lipopolysaccharide
administration were frozen in optimal-cutting-temperature compound
and cut into 50-mm-thick slices. Immunohistochemistry was perfor-
med on floating sections after a 30-min treatment in 0.3% H2O2 in
methanol to remove endogenous peroxides. Primary incubation was
performed overnight at 4C in 5% nonfat dry milk in 50 mM Tris 1
1.5% NaCl and 0.1% Triton X-100, pH 7.2. Iba1 antibody (19-19741;
Wako) was used at a 1:500 dilution. There was a single 5-min wash in
50 mM Tris1 1.5% NaCl and 0.1% Triton X-100, pH 7.2. AVectastain
Elite avidin–biotin complex horseradish peroxidase kit (catalog no. PK-
6101 [Vector Labs]; peroxidase, rabbit IgG) was used for the secondary
and avidin–biotin steps, with the secondary antibody solution being
diluted, per manufacturer protocol, in 5% nonfat dry milk in 50 mM
Tris 1 1.5% NaCl and 0.1% Triton X-100 buffer, pH 7.2. Colorimetric
development was via a 3,3-diaminobenzidine horseradish peroxidase kit
(SK-4100; Vector Labs), and after rinses in deionized water, sections
were dry-mounted on Superfrost Plus (model 12-550-15; Fisher)
charged glass slides, cleared through a progression of increasing
ethanol solutions (80%–100%) followed by immersion in xylene, cover-
slipped, and imaged on an Aperio scanner (Leica Biosystems). Images
were analyzed via manual segmentation of the cortex and hippocampal
regions using Analyze, version 12.0 (AnalyzeDirect), a voxel-based nor-
malized entropy algorithm (n 5 3; 8 technical replicates). In the same
cohort as used for immunohistochemistry, a subset of mice (3 from the
saline group and 4 from the lipopolysaccharide group) were used to
determine the protein levels of P2X7R and b-actin via Western blot
analysis as described in “Cell Line Receptor Expression Validation.”
Radiotracer Biodistribution
Tissue biodistribution of 11C-GSK1482160 was measured in C57BL6
mice administered either saline or lipopolysaccharide (5 mg/kg) and
allowed to incubate for 72 h. At 15, 30, and 60 min after tail-vein tracer
administration of 155 6 10 MBq/kg of 11C-GSK1482160, tissues were
harvested. At the time of harvesting, the animals were deeply anesthe-
tized using isoflurane and cardiac puncture was performed to collect
terminal blood samples. The animals were rapidly decapitated, and the
following organs were removed for analysis: brain, heart, lung, liver,
spleen, kidneys, intestines (small and large), and skeletal muscle. All
samples were placed into vials, weighed, counted via a g-counter
(model 8000; Beckman), and decay-corrected to the time of injection.
Total tissue activity for each subject, tissue or organ, and time point was
expressed according to the following:
%ID
g
ði; j; tÞ 5 Atði; j; tÞ · 100½Wt ði; j; tÞ 2 Wv ði; j; tÞ · ½Dt ði; tÞ 2 Dr ði; tÞ;
Eq. 1
where At, Wt, Wv, Dt, Dr, i, j, and t are the tissue activity, total weight,
vial weight, total dose, residual dose, i’th subject, j’th tissue or organ,
and i’th time point, respectively.
PET and CT Imaging
To determine tracer kinetics under microglial resting–surveilling
and activated states, adult C57BL6 mice were intraperitoneally admin-
istered either saline (n 5 3) or a 5 mg/kg dose of lipopolysaccharide
(O111:B4) (n 5 4) and returned to their home cage for 72 h. At the
time of imaging, the mice were anesthetized using 3%–4% isoflurane
balanced with medical-grade oxygen at a flow rate of 2 L/h. Once
anesthetized, the animals were placed on a custom carbon-fiber bed
and maintained at 1.5%–2% isoflurane, and access was secured via a
27-gauge butterfly catheter into the lateral tail vein. Dynamic list-
mode PET images were acquired using the IndyPET3 scanner (17).
List-mode images were reconstructed into 80 · 100 mm volumes
using filtered backprojection with the following frame durations:
12 · 5 s, 6 · 10 s, 6 · 20 s, 6 · 60 s, and 9 · 300 s. In all cases, images
were corrected for decay, random coincidence events, and dead-time loss
(18). At the completion of the PET procedure, the animal beds were
transferred to an EVS R9 small-animal CT scanner (Enhanced Vision
Systems Corp.) and images were acquired using 80 kVp, 1,000 mA,
200 ms/degree, and 1.08/step and were reconstructed into forty 65-mm
volumes using a vendor-supplied filtered backprojection algorithm. To
determine the specific binding, blocking studies were performed on
lipopolysaccharide-treated mice at 72 h as described above. Approxi-
mately 10 min before 11C-GSK1482160 administration, the mice were
anesthetized, venous access was secured, and a 1 mg/kg dose of authen-
tic standard GSK1482160 was administered intravenously.
Image Analysis
PET and CT images were registered using Analyze (19). To quan-
tify regional activity in mouse brains with time, PET/CT images were
then coregistered to a Paxinos–Franklin (20) mouse brain atlas, and
time–activity curves were extracted and kinetically modeled using a
2-compartment, 5-parameter tracer kinetic model (Fig. 1A) with custom
modeling tools developed by Paul R. Territo for the following brain
regions: retrosplenial dysgranular cortex, cingulate cortex, primary
motor cortex, secondary motor cortex, primary somatosensory cortex,
secondary somatosensory cortex, dysgranular insular cortex, and hip-
pocampus (cornu ammonis 1–3). In addition, image-based arterial
input functions for each mouse were obtained via manual segmenta-
tion of the left ventricle, with care being taken to avoid the septal and
free walls of the myocardium. Regions of interest were then extracted
from the PET time series and were decay-corrected, and a tracer
kinetic model describing 11C-GSK1482160 metabolite-uncorrected
kinetics in left ventricular blood and brain tissue using a 2-tissue-
compartment, 5-parameter model (Fig. 1) was applied:
CPETði; tÞ 5 ð1 2 FbvðiÞÞCT ði; tÞ1FbvðiÞCpðtÞ; Eq. 2
where CPET is the measured 11C-GSK1482160 concentration in the
voxel of interest, CT is the tissue 11C-GSK1482160 concentration, Cp
is the arterial plasma 11C-GSK1482160 concentration using a hemat-
ocrit level of 0.42 (21), Fbv is the fractional blood volume, i is the i’th
brain region, and t is the t’th time point. After fitting of the 2-tissue-
compartment model, the total distribution volume of the P2X7R is
computed as








where VT is the total distribution volume of the P2X7R; K1, k2, k3, and
k4 are the estimated model rate constants; and i is the i’th brain region.
Statistical Analysis
Statistical analysis of the immunofluorescence assay and radio-
immunohistochemistry dose response curves for the cell line receptor
validation studies was performed using Prism, version 6.02 (GraphPad
Software), with 1-way ANOVA in which pairwise analysis was
according to the Tukey multiple-comparison tests. Kinetic modeling
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for association–disassociation kinetics was performed using a nonlin-
ear fit of association and then dissociation, whereas saturation kinetics
were modeled using a 1-site saturation model with Prism. Statistical
analysis of Iba1 immunohistochemistry staining and P2X7R Western
blot analyses was performed in Excel, version 12.0 (Microsoft Corp.)
using an unpaired 1-tailed Student t test with unequal variances. For
tissue biodistribution studies and VT, data were analyzed with 2-way
ANOVA using Prism. The tracer kinetics of mouse brain regions were
modeled using a custom tool (i.e., eNumerate) developed and vali-
dated by our lab. In all cases, data are presented as mean6 SEM, with
statistical significance taken at the P # 0.05 level.
RESULTS
Cell Line Receptor Expression Validation
Dry-mounted and immunofluorescently stained sections of HEK293
cell blocks against P2X7R revealed a statistically significant (P ,
0.0001, 1-way ANOVA, n 5 3; 4 technical replicates) increase in
signal levels with cell density (Fig. 2). Pairwise analysis of immu-
nofluorescence assay intensity with density revealed statistically sig-
nificant differences (P , 0.05, Tukey multipairwise test, n 5 3; 4
technical replicates) for all density levels studied. Given that immu-
nofluorescence assay is reliant on fluorescence emission, which is
subject to inner-filter effects (both primary and secondary) and light
scatter, these measures are considered semiquantitative at best. To
overcome these limitations, we used a new method (radioimmu-
nohistochemistry) that takes advantage of the receptor specificity
afforded by immunohistochemistry and the sensitivity of autoradio-
graphic imaging. Analysis of P2X7R radioimmunohistochemistry
in dry-mounted cell-block sections revealed a statistically signifi-
cant (P , 0.0001, 1-way ANOVA, n 5 3; 4 technical replicates)
increase in tissue activity with cell density. Pairwise analysis of
radioimmunohistochemistry dose levels
showed that virtually all dose levels were
statistically significantly different at P ,
0.05 (Tukey multipairwise test, n 5 3; 4
technical replicates) for all cell density lev-
els studied except 62.5 versus 125 and 250
versus 500 million cells. To further quanti-
tatively probe the expression level as a func-
tion of cell number, Western blot analysis
of P2X7R was performed in serial-diluted
samples from 12,500 to 781 cells and
revealed a clear dose dependence of P2X7R
on cell number.
Radioligand Association–Disassociation and Saturation
Kinetics Experiments
Estimates of the association constant kon, dissociation constant
koff, and binding potential (kon/koff) were 0.2312 6 0.01542 min21
nM21, 0.2547 6 0.0155 min21, and 1.0277 6 0.207, respectively
(Fig. 3A). Provided this, the ratio of total-to-nonspecific binding
was determined over a broad range of 11C-GSK1482160 concentra-
tions (0.15–15,000 pM) in the absence and presence of 10 mM
authentic standard GSK1482160, and Kd and receptor density val-
ues of 1.156 0.12 nM and 3.036 0.10 pmol/mg membrane protein
were obtained, respectively (Fig. 3B). Nonspecific binding in the
presence of an excess of authentic standard GSK1482160 was 5
orders of magnitude below that seen without competitive inhibition.
To demonstrate the specificity of 11C-GSK1482160 to hP2X7R,
total binding was determined in hP2X4R membrane preparations
and showed no affinity to this receptor construct.
Lipopolysaccharide Time Course
Expression levels of Iba1 showed a progressive rise in band
density with increasing time, with the highest expression level
occurring at 72 h after administration (Fig. 4A). By contrast,
b-actin, a cellular housekeeping gene product, showed no eleva-
tion across the time points studied. Ratios of Iba1–to–b-actin band
intensities, which control for sample loading, showed similar re-
sponses in Iba1, with peak expression occurring at 72 h (Fig. 4B)
and being 2.4-fold higher than that for saline. Figure 5 illustrates
coronal brain sections at 72 h after treatment with saline (Fig. 5A)
and lipopolysaccharide (Fig. 5B); the density and morphology of
the microglia have transitioned from a resting–surveying state to a
condensed activated state. This transition can be seen with greater
detail in Figures 5D and 5E, respectively. Quantitative analysis of
FIGURE 1. Schematic diagram of 2-tissue-compartment, 5-parameter tracer kinetic model (A)
and Paxinos–Franklin (18) atlas coregistered (17) to anatomic CT images indicating regions of
interest modeled by Equations 2 and 3 (B).
FIGURE 2. P2X7R expression in HEK293 cell line. (A) WB using anti-P2X7R antibody showing band of expected Kd size increasing in intensity with
increasing number of cells. (B) Immunofluorescence assay on cell blocks showing increased signal with increasing cell number. (C) Radioimmuno-
histochemistry confirming increased signal with increased cell number. Data are mean ± SEM.
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the immunohistochemistry staining indicated a statistically signif-
icant (P , 0.05, Student t test, n 5 3) increase (;1.8-fold) in
average signal enhancement of Iba1 staining. To determine the
P2X7R and b-actin expression, a parallel cohort of mice was in-
jected with saline or lipopolysaccharide, sacrificed, and their frontal
cortex homogenates analyzed via Western blotting at 72 h. As with
Iba1 expression, P2X7R levels increased in the lipopolysaccharide-
treated group, whereas b-actin remained constant. Quantitation of
P2X7R–to–b-actin band-intensity ratios showed a 1.7-fold increase
in receptor expression with treatment (P 5 0.054, Student t test, 3
saline-treated and 4 lipopolysaccharide-treated).
Radiotracer Biodistribution
Compared with saline treatment, lipopolysaccharide treatment
resulted in a statistically significant (P , 0.001, 2-way ANOVA,
n5 3/time and treatment) 2.9- to 5.7-fold increase in total activity
across all organs studied (Figs. 6A–6C).
PET and CT Imaging
The average whole-brain time–activity curves for saline-treated
mice (n 5 3) and lipopolysaccharide-treated mice (n 5 4) show
the characteristic rise in brain tracer levels within the first 5–10 s
after administration of 11C-GSK1482160 and stable tissue levels
within approximately 10 min. As expected, lipopolysaccharide
resulted in a 3.6-fold increase in total brain activity over the time
course (Fig. 7A), and this increase was 97% displaceable when
blocked with a 1 mg/kg dose of authentic standard GSK1482160
over the same time course. In all cases,
the model was fit to a high degree (R2 5
0.915 6 0.037, n 5 10) across all subjects
and treatments. Estimates of VT for the
retrosplenial dysgranular cortex, cingulate
cortex, primary motor cortex, primary so-
matosensory cortex, dysgranular insular
cortex, and hippocampus showed statisti-
cally significant (P, 0.001, 2-way ANOVA,
3 saline-treated and 4 lipopolysaccharide-
treated) increases in regional binding (Fig.
7B). To determine the degree of specific
binding, blocking studies were performed
at 72 h in lipopolysaccharide-treated mice
by intravenously administering a 1 mg/kg
dose of authentic standard GSK1482160
10 min before 11C-GSK1482160 adminis-
tration. As observed with whole-brain analysis, VT significantly de-
creased (P , 0.001, 2-way ANOVA, 4 lipopolysaccharide-treated
and 3 lipopolysaccharide 1 blocking–treated) for all brain regions
studied except the dysgranular insular cortex.
DISCUSSION
Here, we have presented a comprehensive analysis of the
molecular and physiologic characteristics of 11C-GSK1482160, a
novel radioligand for imaging of P2X7R and neuroinflammation.
HEK293 cells expressing hP2X7R were stable and dose-
dependent over a broad range of concentrations, as revealed by
immunofluorescence, radioimmunohistochemistry, and Western
blot analyses (Fig. 1). Inherently, the immunofluorescence and
radioimmunohistochemistry methods provide spatial information
and receptor densities but do so at the cost of sensitivity. As
expected, protein levels via Western blot analysis were signifi-
cantly more sensitive but lacked the spatial information encoding
of the immunofluorescence and radioimmunohistochemistry meth-
ods. The combined data clearly show that the expression levels of
hP2X7R in this system are stable and receptor content–dependent
over a broad range and are suitable for studying receptor kinetics
in membrane preparations.
Given the reliability of the HEK293-hP2X7R cell line, membrane
preparations were generated and used for association–disassociation
and saturation kinetic analyses. The association–disassociation
kinetics showed a high degree of fit across the replicates studied
and yielded consistent kon rates (0.2312
6 0.01542 min21nM21) and koff rates
(0.25476 0.0155 min21), with binding po-
tential (kon/koff) estimates indicating ap-
proximately 100% receptor occupancy by
30 min. These data are consistent with lit-
erature reports of a functional analog of
GSK1482160 that showed rapid onset of
ligand binding and equilibrium within 30–
128 min (22). Saturation kinetic experi-
ments were conducted over a broad range
of concentrations and in the presence of an
excess of authentic standard GSK1482160
and produced a Kd (1.15 6 0.12 nM) that
displays favorable binding kinetics. Simi-
lar results were obtained from association–
disassociation studies (koff/kon), which also
FIGURE 3. (A) Association–disassociation kinetics of 11C-GSK1482160 in membrane prepara-
tions from HEK293 cells expressing hP2X7R. Kd 5 1.10. (B) Saturation binding curve for 11C-
GSK1482160 in absence and presence of excess of parent. Data are mean ± SEM.
FIGURE 4. Time course for increased microglial activation after systemic lipopolysaccharide-
induced inflammation. (A) Western blot of Iba1 protein expression in mouse cortex after lipopoly-
saccharide injection. (B) Ratio of Iba1 expression level to β-actin loading controls. Data are mean
± SEM; n 5 3/time point.
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yielded a comparable Kd (e.g., 1.10 nM) despite being derived from
different preparations and methods. These combined data are con-
sistent with previous reports for antagonists from this drug class in
HEK293-P2X7R membranes, which had a Kd and receptor density
of 1.4 nM and 5.4 pmol/mg, respectively (22). Importantly, 11C-
GSK1482160 specificity to hP2X7R was shown to be selective and
specific for this receptor subtype.
To determine the time course of peripheral cytokine release,
microglial activation, and receptor expression in C57BL6 mice,
lipopolysaccharide time course studies were conducted. Previous
literature reports using the same mouse strain, dose level, and
route of administration were reported to peak within 30 min (23)
when monitored by circulating cytokines and 12 h (24) to 24 h
(25) after lipopolysaccharide administration for microglial activa-
tion as determined via Iba1 expression. In the current study, brain-
derived protein levels of Iba1 (normalized to b-actin) in response
to intraperitoneal lipopolysaccharide administration revealed a
progressive rise in Iba1 content through 72 h (Fig. 4B), which
is significantly longer than previously reported (23–25). It is un-
clear what the differences between these studies may be, but
recent work on the role of gut microflora in germ-free mice sug-
gests that elevated IL10 levels may play a
role in murine immune response to lipopoly-
saccharide (26) and that prior exposure via
gut microflora may play a substantial role in
a heightened immune response. To deter-
mine the morphology and spatial distribution
of microglial activation, immunohistochem-
istry analysis against Iba1 was performed in
the brains of saline- and lipopolysaccharide-
treated mice. As shown in Figures 5A–5D,
administration of lipopolysaccharide at 72 h
resulted in a frank increase in Iba1 staining
over saline, which is consistent with prior
reports at earlier time points (24,25). Inter-
estingly, the magnitude of the response as
measured by image analysis of signal en-
hancement was consistent with Western
blot analysis obtained from the lipopoly-
saccharide time courses at 72 h (Fig. 4B).
Importantly, the expression level of P2X7R/
b-actin in this same system tracks that of
Iba1/b-actin, with a 1.7-fold increase over saline (Figs. 5F–5G).
These data clearly illustrate not only that lipopolysaccharide acti-
vates the microglia, as determined by Iba1/b-actin levels, but that
P2X7R/b-actin is also upregulated during this same interval, consis-
tent with the theory of microglial activation and the role of P2X7R
during this process (6).
To assess the tissue distribution of 11C-GSK1482160 under
baseline and lipopolysaccharide-activated states, biodistribution
studies were performed at 72 h after lipopolysaccharide adminis-
tration. As seen in Figure 6, administration of 11C-GSK1482160
resulted in a range of uptake levels (0.8–23.8 %ID/g) depending
on tissue type and time point studied. As expected, lipopolysac-
charide resulted in a significant increase in tissue uptake for all
tissues and organs studied, with liver showing the largest uptake
overall across time points. These data are consistent with prior
reports implicating liver as a primary route of lipopolysaccharide
clearance during bacterial sepsis (27,28). Moreover, hepatic mye-
loid interstitial dendritic cell ectonucleoside triphosphate diphos-
phohydrolase-1 (CD39) hyporesponsiveness has been reported in
mice (29). Combined, the aforementioned processes would result
in an accumulation of lipopolysaccharide, activation of hepatic
FIGURE 5. Iba1 immunohistochemistry showing increased microglial activation in lipopolysaccharide-
treated mice. (A) Coronal brain section of mouse injected with saline. (B) Coronal brain sections
of mouse injected with lipopolysaccharide after 72 h. (D and E) Respective ·20 magnification of
insets in A and B. (C) Iba1 staining intensity in saline- vs. lipopolysaccharide-treated mice. (F)
Ratio of P2X7R expression level to β-actin in saline- vs. lipopolysaccharide-treated mice. (G)
Western blot of P2X7R protein expression in cortex of lipopolysaccharide-treated mice after
72 h. Data are mean ± SEM. *P , 0.05, unpaired t test.
FIGURE 6. Biodistribution of 11C-GSK1482160 in saline- (white bars) and lipopolysaccharide-treated (5 mg/kg) (black bars) mice 72 h after
administration. Samples were acquired at 15 min (A), 30 min (B), and 60 min (C) after 11C-GSK1482160 administration. Two-way ANOVA showed
that lipopolysaccharide treatment significantly increased tracer biodistribution (P , 0.0001). Data are mean ± SEM; n 5 3/time point.
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Toll-like receptor 4, and suppression of extracellular adenosine-
triphosphate hydrolysis (via CD39 hyporesponsiveness) and thus
stimulate upregulation of P2X7R expression. Although total up-
take was higher in liver than in the other organs collected, uptake
in the brain was approximately 8-fold higher than in saline-treated
animals (Fig. 6). These data, along with previous reports that
GSK1482160 has excellent blood–brain barrier penetration (30),
suggest that binding in activated microglia could be quantified if
dynamically imaged via PET.
To evaluate the in vivo tracer kinetics under resting–surveilling
and activated states, dynamic whole-body 11C-GSK1482160 PET/
CT imaging was performed on mice at 72 h after saline or lipo-
polysaccharide administration. As shown in Figure 7, the admin-
istration of lipopolysaccharide resulted in a marked increase (3.6-
fold) in whole-brain 11C-GSK1482160 uptake, which was consistent
with both the Iba1/b-actin increase and the P2X7R/b-actin in-
crease observed (Fig. 5). The administration of an excess of au-
thentic standard GSK1482160 in lipopolysaccharide-treated mice
resulted in a marked decrease in tracer uptake across all time
points, clearly showing that whole-brain uptake was 97% receptor-
dependent. Tracer kinetic modeling of the individual time courses
revealed a high degree of fit across all subjects studied and all
conditions studied. To evaluate the appropriateness of the model,
koff rate constants from both membrane preparations and PET
kinetic modeling (i.e., k4;koff) were compared, and excellent
agreement was found between in vitro (0.2547 6 0.0155 min21)
and in vivo (0.3296 6 0.0774 min21, n 5 10) measures, suggest-
ing that the model was appropriate for describing the system.
Although the aforementioned tracer kinetic modeling was
performed on metabolite-uncorrected data, which have been
shown to affect interpretation of many PET radiopharmaceuticals
(31), work on GSK1482160 in liver microsomes, liver S9 fraction,
and hepatocytes in multiple species has been shown to be metabol-
ically stable (32). Moreover, in isolated perfused rodent livers no
evidence of hydroxylation has been shown, and in nearly all animal
species studied most of the GSK14822160 parent was recovered
from the urine (32). This is supported by the pharmacokinetic
determination of the GSK14822160 clearance and circulating
half-life, which when modeled are in excess of 2,177 mL/h and
30.5 h, respectively, in humans (derived from (32)). Taken together,
these data suggest that metabolite corrections will have minimal
impact on kinetics if the imaging time is substantially shorter than
the apparent half-life of the parent.
Estimates of VT for 5 of the 8 regions analyzed were signifi-
cantly elevated by 1.6- to 2.1-fold over saline controls (depending
on brain region), again supporting the rationale that the microglia
were activated and P2X7R upregulated by lipopolysaccharide
treatment. Regional analysis of lipopolysaccharide-treated mice pre-
blocked with authentic standard GSK1482160 showed trends sim-
ilar to that of whole-brain analysis, with all but one region showing
significant decreases in VT with treatment. These data clearly illus-
trate the receptor dependence of regional binding in microglia ac-
tivated via peripheral lipopolysaccharide treatment and argue that
these changes in binding are independent of lipopolysaccharide-
mediated changes in blood–brain barrier integrity (33).
The current study provides compelling data that support 11C-
GSK1482160 as a radiopharmaceutical for targeting P2X7R,
which is expressed on the cell surface membranes of myeloid-
derived cells (i.e., macrophages, monocytes, and microglia) during
activation via adenosine-triphosphate (4,5). In particular, P2X7R
has been implicated in microglial proliferation and phagocytosis
of the injured site (6,7) and is a common mechanism among
diseases such as Alzheimer disease, Parkinson disease, Huntington
disease, frontotemporal dementia, atrophic lateral sclerosis, multi-
ple sclerosis, and traumatic brain injury (11–13). Several single-
nucleotide polymorphisms of the P2X7R have been reported, which
include gain-of-function Ala348Thr, Thr357Ser, and Gln460Arg
modifications, and have been suggested to alter both protein struc-
ture and function (34,35). Depending on allelic copy and pene-
trance, these gain-of-function single nucleotide polymorphisms
may result in greater susceptibility to neurodegenerative inflamma-
tory diseases. Moreover, the Glu496Ala single-nucleotide polymor-
phism has been reported to result in loss of function (36,37) and
may result in greater resistance to inflammatory diseases. Depend-
ing on the number of single-nucleotide polymorphisms, penetrance,
and existing risk factors, being able to monitor P2X7R density
FIGURE 7. (A) Graph of dynamic 11C-GSK1482160 average brain PET activity in saline-treated mice (white circles, n 5 3), lipopolysaccharide-
treated mice (black circles, n 5 4), and lipopolysaccharide 1 block–treated mice (gray circles, n 5 3) 72 h after intraperitoneal administration, along
with representative static transverse (top) and sagittal (bottom) PET/CT images. For blocking, 1 mg/kg dose of authentic standard GSK1482160 was
administered intravenously approximately 10 min before tracer. (B) VT reported as measure of ligand binding for saline (white bars), lipopolysac-
charide (black bars), and lipopolysaccharide 1 block (gray bars). Data are mean ± SEM. *Statistically significant difference from saline, P , 0.05.
§Statistically significant difference from lipopolysaccharide, P , 0.05.
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noninvasively via 11C-GSK1482160 may prove beneficial to a wide
array of inflammatory conditions and resulting disease.
CONCLUSION
The initial characterization of 11C-GSK1482160 shows high
affinity and favorable association–disassociation kinetics for
P2X7R. In vivo PET/CT tracer kinetics revealed that VT followed
expected trends for lipopolysaccharide-treated mice and was com-
pletely displaceable with an excess of cold blocking. Taken col-
lectively, these results suggest that 11C-GSK1482160 is suitable
for use as a novel radioligand targeting P2X7R and as a biomarker
of neuroinflammation.
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